Chandan Healthca

Who are the top shareholders of the Chandan Healthca?

The top shareholders of Chandan Healthcare include Amaranita Holdings (India) Private Limited with 16.87%, 11 Foreign Institutional Investors holding 3.86%, and Negen Undiscovered Value Fund at 3.16%. Individual investors own 33.0% of the shares, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Chandan Healthcare include several key players. The majority of the shares are held by promoters, with Amaranita Holdings (India) Private Limited being the largest promoter, holding 16.87%. Additionally, there are 11 Foreign Institutional Investors (FIIs) that collectively hold 3.86% of the company's shares. The highest public shareholder is Negen Undiscovered Value Fund, which holds 3.16%. Individual investors collectively own 33.0% of the shares. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

When is the next results date for Chandan Healthca?

No Upcoming Board Meetings

Has Chandan Healthca declared dividend?

No Dividend History Available

Who are the peers of the Chandan Healthca?

Chandan Healthca's peers include Max Healthcare, Apollo Hospitals, Fortis Health, Narayana Hrudaya, Global Health, Asarfi Hospital, Aashka Hospitals, Aprameya Enginee, Unihealth Hosp, and Nephro Care. Key insights show excellent management and growth at several peers, with Asarfi Hospital leading in 1-year returns at 107.34%, while Chandan Healthca and Aprameya Enginee both report 0.00% returns.

Peers: The peers of Chandan Healthca are Max Healthcare, Apollo Hospitals, Fortis Health., Narayana Hrudaya, Global Health, Asarfi Hospital, Aashka Hospitals, Aprameya Enginee, Unihealth Hosp, Nephro Care.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Global Health, Asarfi Hospital, Fortis Health., and Nephro Care, while Average management risk is found at Aprameya Enginee. Good growth is noted at Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Fortis Health., Unihealth Hosp, and Nephro Care, while Excellent growth is seen at Chandan Healthca, Global Health, and Aprameya Enginee. Below Average growth is present at Aashka Hospitals and Asarfi Hospital, and the rest. Excellent capital structure is attributed to Max Healthcare and Global Health, while Average capital structure is found at Apollo Hospitals and Aprameya Enginee, and Good capital structure is observed at Fortis Health., Narayana Hrudaya, Asarfi Hospital, and Nephro Care, with Below Average capital structure at Aashka Hospitals, Unihealth Hosp, and the rest.<BR><BR>Return Snapshot: Asarfi Hospital has the highest 1-year return at 107.34%, while Aprameya Enginee has the lowest at 0.00%. Chandan Healthca's 1-year return is also 0.00%, which is the same as Aprameya Enginee. Additionally, Apollo Hospitals and Aashka Hospitals have negative six-month returns.

What does Chandan Healthca do?

Chandan Healthcare Ltd operates advanced laboratories offering pathological investigations and diagnostic services in the hospital sector. It is a micro-cap company with a market cap of INR 492 Cr and key metrics including a P/E ratio of 22.00 and a return on equity of 84.79%.

Overview:<BR>Chandan Healthcare Ltd operates state-of-the-art laboratories providing comprehensive pathological investigations and diagnostic services in the hospital industry, categorized as a micro-cap company.<BR><BR>History:<BR>Chandan Healthcare Ltd was established on September 03, 2003. There are no reported status changes, and revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 492 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 22.00<BR>Industry P/E: 59<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.49<BR>Return on Equity: 84.79%<BR>Price-to-Book: 18.87<BR><BR>Contact Details:<BR>Registrar Address: Not available.

How big is Chandan Healthca?

As of 24th July, Chandan Healthcare Ltd has a market capitalization of 583.00 Cr, classifying it as a Micro Cap company. Recent financial data, including quarterly performance, is unavailable, with the latest balance sheet from March 2022 showing Shareholder's Funds of 26.15 Cr and Total Assets of 76.12 Cr.

As of 24th July, Chandan Healthcare Ltd has a market capitalization of 583.00 Cr, categorizing it as a Micro Cap company.<BR><BR>There is no valid financial data available for the latest quarterly performance, including Net Sales and Net Profit for the latest four quarters.<BR><BR>The latest annual period for the balance sheet is March 2022, with Shareholder's Funds reported at 26.15 Cr and Total Assets at 76.12 Cr.

Is Chandan Healthca overvalued or undervalued?

As of August 28, 2025, Chandan Healthcare is considered very expensive and overvalued with a PE ratio of 24.29 and an EV to EBITDA of 13.34, especially compared to peers like Apollo Hospitals and Max Healthcare, and has recently declined by 7.9% against a 2.32% drop in the Sensex, indicating it may not be a favorable investment.

As of 28 August 2025, Chandan Healthcare's valuation grade has moved from fair to very expensive, indicating a significant shift in its market positioning. The company is currently deemed overvalued based on its financial ratios, including a PE ratio of 24.29, an EV to EBITDA of 13.34, and an ROE of 84.79%. These figures suggest that the stock is trading at a premium compared to its earnings and operational efficiency.<BR><BR>In comparison to its peers, Chandan Healthcare's valuation metrics stand out, particularly when contrasted with Apollo Hospitals, which has a PE ratio of 70.56 and an EV to EBITDA of 36.30, and Max Healthcare, which has a PE ratio of 93.61. This highlights that Chandan Healthcare is not only overvalued but also significantly more expensive relative to its competitors in the hospital industry. Furthermore, the recent stock performance shows a decline of 7.9% over the past week, while the Sensex only fell by 2.32%, reinforcing the notion that Chandan Healthcare may not be a favorable investment at its current valuation.

How has been the historical performance of Chandan Healthca?

Chandan Healthca has experienced significant growth from March 2023 to March 2025, with net sales increasing from 136.89 Cr to 230.12 Cr and profit after tax rising from 3.59 Cr to 23.52 Cr, despite facing challenges in cash flow management. Total assets grew from 76.12 Cr to 210.62 Cr, indicating a solid financial position.

Answer:<BR>Chandan Healthca has shown significant growth in its financial performance over the past three years, particularly from March 2023 to March 2025.<BR><BR>Breakdown:<BR>In terms of net sales, Chandan Healthca increased its revenue from 136.89 Cr in March 2023 to 230.12 Cr in March 2025, reflecting a strong upward trend. Total operating income followed a similar trajectory, rising from 136.89 Cr to 230.12 Cr during the same period. The company's total expenditure also grew, from 127.51 Cr in March 2023 to 188.79 Cr in March 2025, with notable increases in raw material costs and employee costs. Operating profit, excluding other income, surged from 9.38 Cr in March 2023 to 41.33 Cr in March 2025, indicating improved operational efficiency. Profit before tax rose significantly from 5.01 Cr to 32.06 Cr, and profit after tax increased from 3.59 Cr to 23.52 Cr, showcasing robust profitability growth. The earnings per share (EPS) also improved markedly from 1.69 to 9.07 over the same period. On the balance sheet, total assets grew from 76.12 Cr in March 2022 to 210.62 Cr in March 2025, while total liabilities increased from 42.05 Cr to 56.88 Cr, indicating a solid asset base. Cash flow from operating activities showed a negative trend, moving from a positive 6.00 Cr in March 2022 to a negative 29.00 Cr in March 2025, although net cash inflow remained positive at 2.00 Cr by March 2025. Overall, Chandan Healthca's performance reflects a strong growth trajectory in sales and profitability, despite challenges in cash flow management.

Which are the latest news on Chandan Healthca?

Why is Chandan Healthcare Ltd falling/rising?

As of 03-Jun, Chandan Healthcare Ltd's stock price is rising to 247.10, up 6.51%. This increase is driven by strong performance metrics, including a low Debt to EBITDA ratio and significant annual operating profit growth, despite some concerns over declining investor participation.

As of 03-Jun, Chandan Healthcare Ltd's stock price is rising, currently at 247.10, reflecting an increase of 15.1 or 6.51%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 4.94% today, indicating strong relative performance. Additionally, despite a year-to-date decline of 23.86%, the stock has shown impressive growth over the past year, generating a return of 30.46%, significantly outperforming the broader market, which has seen negative returns of -1.52% in the same period.<BR><BR>The company's financial health also supports this rise, as it has a low Debt to EBITDA ratio of 1.02 times, demonstrating a strong ability to service its debt. Furthermore, the operating profit has grown at an annual rate of 80.37%, and with a return on capital employed (ROCE) of 20.6, the stock is considered to have a very attractive valuation. The PEG ratio of 0.7 indicates that the stock is undervalued relative to its earnings growth.<BR><BR>However, it is important to note that there are some negative indicators as well, such as a decline in investor participation, with delivery volume falling by 25.17% against the 5-day average. Additionally, domestic mutual funds hold no stake in the company, which may reflect a lack of confidence at current price levels. Despite these concerns, the strong performance metrics and market-beating returns contribute to the current rise in Chandan Healthcare Ltd's stock price.